Jupiter Neurosciences Inc. (NASDAQ: JUNS) is moving into the psychedelic therapeutics market, signing a $100 million term sheet to acquire exclusive U.S. rights for a next-generation MDMA drug candidate, ALA-002, from PharmAla Biotech. The deal positions Jupiter to compete in a sector recently supercharged by a U.S. presidential executive order aimed at accelerating the development of such treatments.
"This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address Longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions," Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, said.
The agreement specifies an upfront payment to PharmAla of $3.33 million, composed of $1.5 million in cash and $1.83 million in Jupiter's common stock. The deal also includes future development milestone payments and single-digit royalties. The companies have 90 days to finalize a definitive agreement, with Jupiter placing $600,000 in escrow which will serve as a reverse termination fee payable to PharmAla if the deal does not close.
The transaction gives capital-constrained Jupiter a highly differentiated asset in a rapidly emerging field. However, with a history of operating losses and reliance on equity financing, investors will be watching how the company manages the development costs for a new clinical program alongside its existing Phase IIa trial for Parkinson's disease.
A Safer MDMA Alternative
ALA-002 is a patented, non-racemic formulation of MDMA that has been recognized by the U.S. Food and Drug Administration as a Novel Chemical Entity (NCE). It was engineered to reduce the cardiovascular risks and abuse potential associated with traditional racemic MDMA, while preserving the pro-social and therapeutic effects crucial for MDMA-assisted therapy for conditions like PTSD and anxiety.
PharmAla, which developed the molecule, is a key supplier for U.S. government-sponsored clinical trials at the Department of Veterans Affairs (VA) and the Defense Health Agency (DHA), giving its manufacturing process real-world validation.
Favorable Regulatory Tailwinds
The deal comes just over a month after an April 18, 2026, Executive Order from President Donald J. Trump directed federal agencies to expand access to and accelerate the development of investigational psychedelic therapies. The order included $50 million in funding through the Advanced Research Projects Agency for Health (ARPA-H) and created pathways for expedited review of designated "Breakthrough" therapies.
This federal support underpins analyst projections that the regulated U.S. market for psychedelic therapeutics could reach between $6 billion and $15 billion in annual sales in the early-to-mid 2030s. By acquiring the rights to a clinical-stage, NCE-designated asset, Jupiter is aiming to capture a significant share of this nascent market.
This article is for informational purposes only and does not constitute investment advice.
